Table 1.
Description of the clinical characteristics of the study population.
| Variables | Total (N = 690) | Combined treatment (N = 327) | Conventional treatment (N = 363) | P valuesa |
|---|---|---|---|---|
| Sex [male, N(%)] | 438 (63.5) | 203 (62.1) | 235 (64.7) | 0.477 |
| Age (years) | 65.1 ± 11.32 | 65.13 ± 11.28 | 65.07 ± 11.38 | 0.942 |
| BMI (Kg*m-2) | 25.57 ± 1.69 | 25.51 ± 1.72 | 25.63 ± 1.67 | 0.382 |
| Physical activity [Hgih, N(%)] | 297 (43.0) | 151 (46.2) | 146 (40.2) | 0.124 |
| Smoking [N(%)] | 427 (61.9) | 201 (61.5) | 226 (62.3) | 0.875 |
| Alcohol consumption [N(%)] | 330 (47.8) | 196 (59.9) | 134 (36.9) | <0.001 |
| Hypertension [N(%)] | 280 (40.6) | 130 (39.8) | 150 (41.3) | 0.698 |
| Diabetes [N(%)] | 234 (33.9) | 104 (31.8) | 130 (35.8) | 0.295 |
| Hyperlipemia [N(%)] | 222 (32.2) | 92 (28.1) | 130 (35.8) | 0.034 |
| Carotid atherosclerosis [N(%)] | 245 (35.5) | 127 (38.8) | 118 (32.5) | 0.094 |
| Stroke [N(%)] | 78 (11.3) | 37 (11.3) | 41 (11.3) | <0.999 |
| Renal insufficiency [N(%)] | 28 (4.1) | 12 (3.7) | 16 (4.4) | 0.701 |
| Antiplatelet [N(%)] | 599 (86.8) | 287 (87.8) | 312 (86.0) | 0.501 |
| Antianginal [N(%)] | 101 (14.6) | 46 (14.1) | 55 (15.2) | 0.747 |
| Nitrate ester [N(%)] | 142 (20.6) | 67 (20.5) | 75 (20.7) | <0.999 |
| ACEI/ARB [N(%)] | 303 (43.9) | 140 (42.8) | 163 (44.9) | 0.592 |
| β-blockers [N(%)] | 367 (53.2) | 171 (52.3) | 196 (54.0) | 0.703 |
| CCB [N(%)] | 206 (29.9) | 94 (28.7) | 112 (30.9) | 0.561 |
| Anticoagulant [N(%)] | 62 (9.0) | 25 (7.6) | 37 (10.2) | 0.286 |
| Lipid-lowering [N(%)] | 611 (88.6) | 275 (84.1) | 336 (92.6) | 0.001 |
| Gensini score | 23.00 (10.00, 47.25) | 23.00 (12.00, 50.00) | 22.00 (10.00, 47.00) | 0.471 |
| Hcy (μmol*L-1) | 15.00 ± 7.39 | 15.16 ± 8.86 | 14.85 ± 5.77 | 0.584 |
| LDL-C (mmol*L-1) | 2.35 ± 0.71 | 2.38 ± 0.72 | 2.32 ± 0.70 | 0.247 |
| Lp-a (mg*L-1) | 124.02 (56.12, 223.89) | 116.7 (56.12, 183.29) | 133.77 (52.00, 253.86) | 0.057 |
| HbA1c (%) | 6.34 ± 2.93 | 6.12 ± 1.31 | 6.53 ± 3.84 | 0.063 |
| Urea (mmol*L-1) | 17.36 ± 8.10 | 16.75 ± 8.31 | 17.91 ± 7.87 | 0.059 |
| Scr (mg*dL-1) | 0.96 (0.82, 1.15) | 0.92 (0.81, 1.11) | 0.99 (0.82, 1.17) | 0.005 |
| SAQ of Exertional capacity | 61.67 ± 15.37 | 59.72 ± 16.81 | 61.32 ± 15.09 | 0.189 |
| SAQ of Anginal stability | 50.67 ± 22.13 | 52.25 ± 23.39 | 49.72 ± 21.19 | 0.755 |
| SAQ of Anginal frequency | 75.86 ± 20.76 | 75.50 ± 25.12 | 74.72 ± 16.24 | 0.653 |
| SAQ of Disease perception | 65.48 ± 17.13 | 64.13 ± 18.95 | 65.31 ± 15.31 | 0.367 |
| SAQ of Treatment satisfaction | 80.49 ± 11.37 | 80.13 ± 11.88 | 79.38 ± 11.43 | 0.399 |
| AR [N(%)] | 60 (8.7) | 19 (5.8) | 41 (11.3) | 0.014 |
| CVEs [N(%)] | 56 (8.1) | 19 (5.8) | 37 (10.2) | 0.037 |
a
Differential analysis of the data between the “Combined treatment” and “Conventional treatment” groups, with bolded values representing statistical significance.